Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | RXRB | P28702 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171006 | 0.83 | TPMT (0.44) | TPMTHCAR1RXRARXRBRAB9A | |
| SCHEMBL2172128 | 0.83 | TPMT (0.44) | TPMTHCAR1KDRHCAR2PARP1 | |
| SCHEMBL4465360 | 0.79 | TPMT (0.65) | TPMTTSHRHCAR1RXRARXRB | |
| SCHEMBL93282 | 0.77 | TPMT (0.62) | TPMTTSHRHCAR1RXRARXRB | |
| SCHEMBL28214359 | 0.77 | TPMT (1.00) | TPMTTSHRHCAR1RXRARXRB | |
| SCHEMBL19998298 | 0.77 | TPMT (0.62) | TPMTTSHRHCAR1RXRARXRB | |
| SCHEMBL23699 | 0.77 | TPMT (1.00) | TPMTTSHRHCAR1RXRARXRB | |
| SCHEMBL9586456 | 0.74 | TPMT (0.59) | TPMTTSHRHCAR1RXRARXRB | |
| SCHEMBL111207 | 0.74 | TPMT (0.59) | TPMTTSHRHCAR1RXRARXRB | |
| SCHEMBL2095666 | 0.74 | TPMT (0.59) | TPMTTSHRHCAR1RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030036661-A1 | 2-Aroyl-4-acyl paclitaxel (taxol) analogs | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-20 | — | — | US | claimed |
| EP-1067923-A4 | 2-AROYL-4-ACYL PACLITAXEL (TAXOL) ANALOGS | BRISTOL MYERS SQUIBB CO (US) | 2002-11-13 | — | — | EP | claimed |
| EP-1067923-A1 | 2-AROYL-4-ACYL PACLITAXEL (TAXOL) ANALOGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999033462-A9 | 2-AROYL-4-ACYL PACLITAXEL (TAXOL) ANALOGS | KINGSTON DAVID GEORGE IAN (US) | 1999-09-30 | — | — | WO | claimed |
| WO-1999033462-A1 | 2-AROYL-4-ACYL PACLITAXEL (TAXOL) ANALOGS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 1999-07-08 | — | — | WO | claimed |
| US-10022454-B2 | Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis | LIPOSCIENCES, LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170224832-A9 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2017-08-10 | — | — | US | disclosed |
| EP-3067359-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | Petersen, Scott G. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20140329775-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2014-11-06 | — | — | US | disclosed |
| US-20110294869-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | TRAVERSA THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2346883-A2 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | Traversa Therapeutics, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010039543-A2 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | TRAVERSA THERAPEUTICS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-0450097-B1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1996-04-24 | — | — | EP | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5262385-A | Pyrimidine ring containing | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1993-11-16 | — | — | US | disclosed |
| EP-0468766-A1 | Halogen-containing compounds, herbicidal composition containing the same as an active ingredient, and intermediary compounds therefor | Mitsubishi Chemical Corporation (JP) | 1992-01-29 | — | — | EP | disclosed |
| EP-0450097-A1 | BENZOHETEROCYCLIC COMPOUNDS. | OTSUKA PHARMA CO LTD (JP) | 1991-10-09 | — | — | EP | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
| US-4113939-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329775-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | TPMT 3886/4885TSHR 3741/4885HCAR1 4112/4885 |
| US-20110294869-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | TPMT 3886/4885TSHR 3741/4885HCAR1 4112/4885 |
| US-10022454-B2 | Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis | NCL, PHOSPHO1, POLN | TPMT 3047/4885TSHR 2644/4885HCAR1 4052/4885 |
| US-20170224832-A9 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | TPMT 3886/4885TSHR 3741/4885HCAR1 4112/4885 |
| US-20030036661-A1 | 2-Aroyl-4-acyl paclitaxel (taxol) analogs | HDAC6, HDAC3, ACAT2 | TPMT 3641/4885TSHR 4728/4885HCAR1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.